Evaxion Biotech A/S
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $28.5M
- Price
- $3.16
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 21.8K
About
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Quick stats
Shares outstanding9.0M
Computed float7.3M
Float / shares81.3%
Cash runway (months)8.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001828253
Websitehttps://evaxion.ai
AI Summary
AI-generated1/20
minorbullishclinical trial
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Evaxion will present new immune profiling data for its lead AI-designed personalized cancer vaccine EVX-01 in both an oral and poster presentation at the SITC 2026 Annual Meeting, November 4-8 in Phoenix.
The data comes from the phase 2 trial of EVX-01 plus Merck's KEYTRUDA (pembrolizumab) in advanced melanoma and highlights systemic immunomodulatory effects beyond vaccine-specific T-cell responses.
Complete three-year clinical data, including year three where EVX-01 was given as stand-alone therapy, will be presented at the ESMO 2026 congress on October 24, 2026.
Previously reported two-year data showed a 75% objective response rate (12 of 16 patients, four complete responses) with 92% of patients still responding and no relapses observed.
Red flags
- announcement contains no new clinical data — actual results deferred to SITC and ESMO presentations